2.750EUR+3.00%Mkt Cap: 128.66M EURP/E: —Last update: 2026-06-01
Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, Europe, China, the United States, and internationally. The company's lead product candid…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap128.66M EUR
Enterprise Value115.73M EUR
Revenue (TTM)3.22M EUR
Gross Profit1.19M EUR
Net Income (TTM)-42.28M EUR
Revenue/Share0.0680 EUR
Last Price2.750 EUR
Fiscal Year EndDec 2019
MR QuarterFeb 2026
Employees60
CountryDE
SectorHealthcare
IndustryBiotechnology
ISINDE000A11QVV0
Valuation
P/E (Trailing)—
P/E (Forward)-13.27
PEG5.46
EV/EBITDA-2.51
EV/Revenue35.95
P/S38.81
P/B-8.37
EPS (TTM)-0.87
EPS (Forward)-0.20
52W Range
2.33014% of range5.360
52W High5.360 EUR
52W Low2.330 EUR
Profitability
Gross Margin81.31%
Oper. Margin-168.14%
EBITDA Margin0.00%
Profit Margin-2901.15%
ROE387.26%
ROA-110.87%
Growth
Revenue Growth138.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-31.60M EUR
CapEx (TTM)135.05K EUR
FCF Margin-564.18%
FCF Yield-14.12%
Net Debt-9.18M EUR
Net Debt/EBITDA0.20
Balance Sheet
Debt/Equity-0.01
Current Ratio2.40
Quick Ratio1.29
Book Value/Sh-0.3190 EUR
Cash/Share0.1980 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:4
Split DateJul 18, 2014
Analyst Consensus
Rating—
Target (Mean)6.750 EUR
Target Range5.500 EUR – 8.000 EUR
# Analysts2
Ownership
Shares Out.46.78M
Float9.97M
Insiders78.83%
Institutions2.34%
Technical
SMA 502.813 (-2.2%)
SMA 2002.997 (-8.2%)
Beta0.74
S&P 52W Chg27.70%
Avg Vol (30d)3.24K
Avg Vol (10d)2.62K
Technical Indicators
RSI (14)41.3
MACD-0.0353
MACD Signal-0.0286
MACD Hist.-0.0067
BB Upper2.879 EUR
BB Middle2.764 EUR
BB Lower2.648 EUR
BB Width8.33%
ATR (14)0.0853 EUR
Vol Ratio (20d)3.17x